Presentation ESC 2024 QUADRO Phase III Study: Efficacy and Safety of the new Quadruple SPC Perindopril/Indapamide/Amlodipine/Bisoprolol in Patients with Resistant Hypertension Presenter: Stefano Taddei August 31, 2024
Presentation ESC 2024 Continuation versus Interruption of Oral Anticoagulation during TAVI Presenter: Dirk-Jan van Ginkel August 31, 2024
News Conference News ESC 2024 New BedMed Data Confirm Antihypertensives Can Be Taken Any Time of Day Yael L. Maxwell August 31, 2024
News Conference News ESC 2024 Polypills Show Promise in Diverse Hypertensive Patient Groups L.A. McKeown August 31, 2024
News Conference News ESC 2023 ESC Issues New ACS Guidelines: Directions on Invasive Timing, DAPT, and More Michael O'Riordan September 06, 2023
News Conference News ESC 2023 ESC Focused Update on HF Synthesizes New Trial Data for Practical Use L.A. McKeown September 01, 2023
News Conference News ESC 2023 ORION-8: Safe and Durable Longer-Term LDL-Lowering With Inclisiran Michael O'Riordan September 01, 2023
News Conference News ESC 2023 More Details on Acoramidis’ Benefit in ATTR Cardiomyopathy: ATTRibute-CM Michael O'Riordan August 31, 2023
News Conference News ESC 2023 ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients L.A. McKeown August 30, 2023
News Conference News ESC 2023 New ESC Guidelines for CVD in Patients With Diabetes Cover Wide Ground Caitlin E. Cox August 30, 2023
News ESC 2023 Qiliqiangxin, a Traditional Chinese Medication, Cuts CV Events in HF: QUEST Michael O'Riordan August 27, 2023
News Conference News ESC 2022 CV Care Around Noncardiac Surgery: New ESC Guidelines Michael O'Riordan September 07, 2022
News Conference News ESC 2022 COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19 Todd Neale September 01, 2022
News Conference News ESC 2022 Large RCTs of High-Dose Flu Vaccines Doable, DANFLU-1 Confirms Yael L. Maxwell August 31, 2022
News Conference News ESC 2022 Earlier Evolocumab Cut CVD, CV Mortality Over Longer Term: FOURIER-OLE Michael O'Riordan August 31, 2022
News Conference News ESC 2022 Only Very Small Risk of Muscle Symptoms With Statins: CTT Collaboration Michael O'Riordan August 29, 2022
Presentation ESC 2022 Long-Term Evolocumab in Patients with Established Atherosclerotic Cardiovascular Disease: Primary Results of the FOURIER-OLE (Open-Label Extension) Studies Presenter: Michelle L. O’Donoghue August 29, 2022
Presentation ESC 2022 Colchicine and Aspirin in Community Patients with COVID-19: An Open-label, Factorial, Randomized Trial Presenter: John Eikelboom August 29, 2022
Presentation ESC 2022 Colchicine and Rivaroxaban Plus Aspirin in Patients Hospitalized with COVID-19: A Factorial, Randomized, Open Trial Presenter: Sanjit Jolly August 28, 2022
News Conference News ESC 2022 INVICTUS: More Deaths, Stroke With Rivaroxaban in Rheumatic Heart Disease AF Michael O'Riordan August 28, 2022